Advertisement
Advertisement
U.S. Markets open in 4 hrs 17 mins
Advertisement
Advertisement
Advertisement
Advertisement

AIM ImmunoTech Inc. (AIM)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.7305+0.0053 (+2.73%)
At close: 03:59PM EDT
0.7109 -0.03 (-4.58%)
Pre-Market: 04:39AM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • T
    Tom
    The company used to report their accumulated losses over their history in their 10-K's. But sometime after Equels became CEO they switched accountants and they stopped reporting this info. But, here is a 10-K that did report this information:

    "Hemispherx is a specialty pharmaceutical company headquartered in Philadelphia, Pennsylvania and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. We were first formed in 1966 ...We last reported net profit from 1985 through 1987. Since 1987, with a major emphasis on new drug diagnostic and development, we have incurred substantial operating losses, as we pursued our clinical trial effort to get our experimental drug, Ampligen®, approved. As of December 31, 2016, our accumulated deficit was approximately $300,501,000. We have not yet generated significant revenues from our products and may incur substantial and increased losses in the future. We cannot assure that we will ever achieve significant revenues from product sales or become profitable. We require, and will continue to require, the commitment of substantial resources to develop our products. We cannot assure that our product development efforts will be successfully completed or that required regulatory approvals will be obtained or that any products will be manufactured and marketed successfully, or be profitable."

    $300,000,000+ wasted over five decades. And yet they can still find some poor souls willing to believe: "But, but, this time is different!"
  • T
    Tom
    From the last 10-Q:

    "Loss on investments for the three months ended March 31, 2022, and 2021 represents a loss of approximately $934,000, driven primarily from the unrealized loss on securities of $915,000."

    They were never very clear on what it was that they invested in that lost almost $1 million.

    Was the investment in a horse farm in Ocala, FL? Who knows?
  • T
    Tom
    We may be getting near the date which the the deadline for which you can be a stockholder of record for the purpose of voting at the shareholders meeting.

    It may be possible that buying of shares by the "Activist Group" was propping up the share price, and that when they stop buying, the share price will drop. We may even be seeing signs of that already.

    The company's Sched 14A filing ought to be out soon, and that will have the deadline in it.
  • T
    Tom
    From the recent DFAN 14-A filing:

    "Compensation of CEO Equels and directors Mitchell and Appelrouth is egregiously excessive for a company with such a small market cap of just $35 million and a consistent history of significant losses and a lack of clinical or commercial progress. In the past two years alone, Equels has received average total compensation of over $2.2 million per year, of which an average of over $1.3 million per year was cash. In the past two years, directors Mitchell and Appelrouth have each received average total compensation of over $275,000 per year, with over $180,000 per year paid in cash. In fact, since 2010, Equels and Mitchell have paid themselves $15,778,512 and $2,256,525 respectively, while Appelrouth since 2016 paid himself $1,040,199 – $19,075,236 cumulative total compensation for all three! This is an outrageous amount of money paid out to AIM’s CEO and Board in light of AIM’s severe lack of execution and performance and its massive losses. Stockholders are losing their money and equity while management gets filthy rich by rewarding themselves with cash and stock options."

    I suppose that this part is all true. But, I suspect that, in the end, the activist group would be as likely to enrich themselves as the current crew.
  • T
    Tom
    On February 25, 2016, the Board of Directors of Hemispherx Biopharma, Inc. (the “Company”) appointed Thomas K. Equels, the current President of the Company, as the Company’s Chief Executive Officer. In that capacity, he is the principal executive officer of the Company. "

    Adjusting for the reverse stock splits, HEB/AIM traded for $100.32 per share on Feb 25, 2016.

    From $100.32 per share to $0.73 per share is a loss of 99.27%

    Short interest in HEB/AIM is still tiny (1.25% of the float). But for those few who are actually short $AIM, they must surely be rooting for Equels to stay at the helm given the performance of the company's share price under his leadership.
  • T
    Tom
    I'm surprised that mike/TakeAim/polakowski/hebmaster/jonjonson/Aimdude/manofscyence is criticizing Franz Tudor. I thought that he would feel simpatico towards Franz as they both spend their time pumping AIM on social media and internet message boards as a way to try to audition to become a paid boiler room pumper.

    From the company's recent press release:

    "Mr. Tudor was indefinitely enjoined by a judge in Marion County, Florida from contacting any of AIM’s business relations after he attempted to be retained by the Company as an international business development consultant, was rejected based upon his criminal history of insider trading, but then went on to give the impression to third parties, such as principal investigators in clinical trials, that he was part of the Company."

    But, maybe instead of feeling simpatico, he sees Franz as a rival. Maybe he is jealous of Franz.

    Of course, mike's mind is twisted like a Hall of Mirrors, and so it is not really worth spending too much time trying to figure out his motivations.
  • T
    Tom
    Opinions may vary, but I still think it was a very serious error for HEB/AIM to submit misleading safety data for Ampligen to the FDA.

    Here is what the FDA said on this matter:

    "The safety assessment of Ampligen revealed a number of discrepancies in the sponsor’s data. Key issues include some serious adverse events not counted by the sponsor, marked laboratory abnormalities that were not reported in the database, miscoding of adverse events and reasons for discontinuation, lack of adverse event definitions, and misleading or incomplete presentations of data. These discrepancies raise significant questions about data from all of the trials and whether or not the data are sufficient to determine the safety profile of Ampligen. "
  • c
    cindy
    I haven't looked in 2 months because i trust somwane I think that someone's prediction will come true the long shareholder will be rewarded 50$
  • T
    Tom
    When HEB/AIM shareholders receive the proxy (or proxies) for this years meeting, they will face a choice between The Three Stooges (the incumbents) vs Frank, Mac and Charlie from The Gang from It's Always Sunny in Philadelphia (the insurgents).

    The current Stooges are mostly bumbling, though are also self-serving. The insurgents might be slightly less bumbling, but might have more a propensity for malfeasance.

    But the bigger issue is that the thing that they are fighting over is control of "Ol Doc Carter's Old-Tyme Cure-All Elixir" that is "Guaranteed to fix every malady known to mankind from Alzheimers to Zika!!!"

    Getting a proxy, (or proxies) for HEB/AIM is kind of like getting a booby prize. If you see a proxy from HEB/AIM in your mail, the reaction is "Oh shoot! I must be way more gullible and impulsive than I had realized if somehow I ended buying shares of this company. Golly, I really need to learn not to trust my judgement when it comes to investing, because if I bought these shares, I must have really poor judgement."
  • T
    Tom
    I suspect that mike/TakeAim/jonjonson/hebmaster/Aimdude/manofscyence must feel some kinship for Franz Tudor.

    From the company's recent press release:

    "Mr. Tudor was indefinitely enjoined by a judge in Marion County, Florida from contacting any of AIM’s business relations after he attempted to be retained by the Company as an international business development consultant, was rejected based upon his criminal history of insider trading, but then went on to give the impression to third parties, such as principal investigators in clinical trials, that he was part of the Company."

    Both mike and Franz Tudor seem to spend their time auditioning to be boiler room pumpers for junky biotechs, hoping to get hired as a stock promoter.
  • T
    Tom
    In the Frater vs Hemispherx case, things were looking pretty bad for HEB/AIM, which is why they had to settle.

    Here is what the Judge in the case wrote:

    "Here, the plaintiffs' allegations of misleading material statements are accompanied by substantial evidence suggesting the defendants knew or should have known of those statements' misleading nature, if in fact they were misleading.

    First, statements characterizing the feedback Hemispherx received from the FDA at the June 8 meeting imply that speakers knew the entirety of the FDA's feedback, including its concurrent warning that it would be unusual for a resubmitted NDA to succeed based on reanalysis of previously submitted data.

    Second, statements that the FDA withdrew its request for an additional study appear to have been outright false according to the complaint, without any reason for speakers to believe a basis in truth.

    Third, as to statements lauding the results of the Ampligen trials, Hemispherx, Carter, and Strayer are all alleged to have been in position to know of departures from protocol, statistical manipulation, and the like.

    Fourth, regarding statements misrepresenting the level of external review, Hemispherx, Carter, and Strayer would have known of PLoS One's self-publish model because they oversaw publication in PLoS One and moreover they would have known of the departures from protocol that rendered FDA approval of protocol moot.

    Fifth, regarding statements representing the relevance of the PDUFA statutory updates to the Ampligen application, to the extent these statements were categorically false and there was no basis for the asserted belief, there is, at a minimum, a cogent inference of recklessness to the truth.

    Even as to Hemispherx's confident predictions about the outcome of its Ampligen resubmission, "[w]hen the FDA tells a company about problems with a product, and the company nonetheless continues to make confident predictions about a product, courts have inferred scienter and falsity." "
  • B
    Ben
    It's been many many years now that I am waiting anxiously for the thisismyself clown to finally reveal, as he promised about a hundred thousand times, all my personal details and those of the so said criminal network behind the zillion counterfeit shares manipulation of this biopharma germ. Up and till today, in vain. So it looks that all his threats, just like all his predictions, was just the usual hogwash of a bunch of nitwits, aka the hem/heb/aim pump gang. Oh well, it was all big fun, lots of laughter, and not to forget, lots of easy money earned shorting any and every uptick after yet another bogus pr of this scam vehicle. Time to spend it now.
  • T
    Tom
    The FDA was quite dismayed by the company's attempts to conceal and undercount Serious Adverse Events (SAEs) in the Ampligen studies.

    Here is what the FDA wrote:

    "According to the sponsor, there were 14, 22, and 24 SAEs in trials AMP-502, AMP-511, and AMP-516, respectively. FDA review of the adverse event (AE) databases for these trials revealed that there were a number of AEs listed with an outcome of hospitalization that were not counted by the sponsor as SAEs, as per the regulatory definition of serious.
    Including hospitalization events as SAEs, the Agency review found 35, 49 and 48 SAEs in studies AMP-502, AMP-511, and AMP-516, respectively. The FDA’s SAE list is an underestimate because it is based solely on the AE data listing from the sponsor, and source documents were not reviewed. Review of SAE narratives reveal that there are several cases in which additional SAEs likely occurred, but were reported only as a single event. …These discrepancies raise a number of concerns about whether or not SAEs were correctly reported, especially since only trials AMP-509 and AMP-516 provided a definition of SAEs to investigators in the study protocol; it is unclear what reporting criteria were used in the other trials."

    From 14, 22, 24 to 35, 49, 58 is a doubling of SAEs. So HEB/AIM tried to report less than half of the severe adverse events from Ampligen to the FDA and to conceal the other half.

    Also, for such small studies, these are fairly large numbers of SAEs.

    Thankfully, the FDA was not deceived and is still doing its job of protecting the general public from unsafe medications such as Ampligen.
  • T
    Tom
    "Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. "

    Alas, all of mike's wisdom about recycled monkey lungs and intra-day OBV analysis and BARDA grants and FDAISA and "the Cronix test" and XMRV and double-secret contracts with Biken will be lost.

    What a pity for future generations...
  • L
    Luc
    Lying about everything and stealing money from naive investors = the core business of every scam ...
  • T
    Tom
    From today's press release:

    "The preliminary data from this uncontrolled clinical trial found..."

    Data from an uncontrolled study in this circumstance is totally worthless.

    All of their press releases are designed to fool unsophisticated investors into believing that Ampligen has some value.
  • J
    Joseph
    What is AIM going to do with that new research center it just began leasing in new jersey?
    Based on our discussions with AIM, Amarex understands that AIM plans to conduct a trial entitled: “A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients with Post-COVID Conditions.” The study will be conducted at up to 10 sites in the United States. No interim analysis is planned.
  • T
    TakeAim
    ASFV committee??? LOL, What a joke. The filing reads like it was written by a third grader having a temper tantrum. The hedgies are having a melt down... desperation sets in as they were not counting on Equels being able to turn the company around.

    ASFV committee... too funny.
  • E
    Edward
    Same up premarket only to go down at opening highly manipulated 😤
  • T
    Tom
    Lol, the polakowski aliases are as silly as ever.

    "they were counting on the company going bankrupt because they cannot possibly come close to covering their position."

    Float 47.4M
    % Held by Insiders 1.45%
    Shares Short (Jun 30, 2022) 592.07k
    Short Ratio (Jun 30, 2022) 3.28
    Short % of Float (Jun 30, 2022) 1.25%
    Short % of Shares Outstanding (Jun 30, 2022) 1.23%
    Avg Vol (3 month) 172.46k

    I have never had any position in HEB/AIM, neither long nor short. But anyone who is short can cover their position quite easily because short interest remains tiny.

    Also, the percent of shares owned by insiders also remains tiny, which I suppose opened them up to another group of scam artists who want to take Ampliscam away from Equels & Co. via a proxy fight. Alas, alas, c'est la vie.
Advertisement
Advertisement